⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for advance solid tumor

Every month we try and update this database with for advance solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385
RET-altered Non...
Medullary Thyro...
RET-altered Pap...
RET-altered Col...
RET-altered Sol...
Lung Neoplasm
Carcinoma, Non-...
Thyroid Disease...
Thyroid Neoplas...
Thyroid Cancer,...
Carcinoma, Neur...
Respiratory Tra...
Thoracic Neopla...
Neoplasms by Si...
Neoplasms
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Endocrine Syste...
Endocrine Gland...
Head and Neck N...
Adenocarcinoma,...
Adenocarcinoma
Carcinoma
Neoplasms, Glan...
Neoplasms by Hi...
Neuroendocrine ...
Neuroectodermal...
Neoplasms, Germ...
Neoplasms, Nerv...
Colonic Neoplas...
Colorectal Neop...
Intestinal Neop...
Gastrointestina...
Digestive Syste...
Digestive Syste...
Gastrointestina...
Colonic Disease...
Intestinal Dise...
pralsetinib (BL...
18 Years - Hoffmann-La Roche
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal ImpairmentNCT02301117
Advanced Solid ...
TAS-102
18 Years - Taiho Oncology, Inc.
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: